Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

February 05, 2025, 03:25 AM ET, BY Thomas H. Kee Jr, Editor, Stock Traders Daily | Editor: Derek Curry ( Follow on LinkedIn ) ...

EST Cathie Wood’s ARK Investment buys 77.6K shares of 10x Genomics (TXG) todayMaximize Your Portfolio with Data Driven Insights:Leverage ...

Construction substantially complete and first copper concentrate on track for March (All amounts expressed in U.S. dollars ...

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report).

Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive ...

Nisa Investment Advisors LLC acquired a new position in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) in the 4th quarter, HoldingsChannel reports. The firm acquired 16,500 shares of the ...

Life sciences stocks fell Thursday after Science reported that newly imposed restrictions on the NIH by the Trump ...

Cathie Wood-led Ark Invest made significant trades involving CRSP, TXG, RBLX, ACHR, NU, ADYEY, ACCD, and AVAV.

Cathie Wood and Ark Invest sold roughly $7,379,804 worth of Palantir stock — and spent $9,145,824 on three biotech stocks.